Breaking Finance News

BWS Financial announced Verso (CVE:VRS), stepping up its target to $15.00 earlier today

Verso (CVE:VRS) had its target bumped up to $15.00 by BWS Financial in an issued report announced 10/18/2017. The bumped up target implies a potential upside of 1.59% from the company's last closing price.

Just yesterday Verso (CVE:VRS) traded 0.00% even at $5.80. VRS’s 50-day average is $0.00 and its two hundred day average is $0.00. With the last stock price close up 0.00% relative to the two hundred day average, compared with the S&P 500 Index which has increased 0.03% over the same time period. 0 shares of VRS traded, down from an average trading volume of 0

Performance Chart

Verso (CVE:VRS)

With a total market value of $0, Verso has with a 52 week low of $0.00 and a one year high of $0.00 .

General Company Details For Verso (CVE:VRS)

Verisante Technology, Inc. is a medical device company focusing on commercializing systems for the early detection of cancer. The Company's device, called the Verisante Aura can be used in the early detection of all forms of skin cancer, including basal cell and squamous cell carcinoma and melanoma. The Verisante Core device is based on the same platform technology as the Aura and can be used in the early detection of lung, cervical, gastrointestinal and colorectal cancers. Verisante Aura is a spectroscopy system designed to aid in the detection of skin cancer. This system provides information about the chemical composition of the skin non-invasively. Aura scans for different spectral markers. Verisante Core uses an endoscopic attachment to aid in the detection of lung, colon, cervical, and other cancers. It has completed a second Phase prototype of a rapid Multispectral Imaging camera (MSI) system for skin cancer detection.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.